- Home
- ARKO vs ATXS Comparison
ARKO vs ATXS Comparison
Compare ARKO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARKO | ATXS |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 722.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARKO | ATXS |
|---|---|---|
| Price | $5.08 | $12.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | $7.50 | ★ $24.33 |
| AVG Volume (30 Days) | 415.7K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,887,822,000.00 | $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $3.56 |
| 52 Week High | $7.84 | $13.29 |
Technical Indicators
Market Signals| Indicator | ARKO | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 69.60 | 64.63 |
| Support Level | $4.83 | $12.87 |
| Resistance Level | $5.14 | $13.29 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 92.68 | 63.68 |
Price Performance
Historical ComparisonAbout ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.